Skip to main content

Table 2 Ischemic stroke risk of different lipoprotein (a) levels (mg/dL) in patients with non-valvular atrial fibrillation

From: Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study

Lp (a) Events, n (%) Crude model Model1 Model 2 Model 3
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Q1 (<  7.1) 289 (7.0) 1.00   1.00   1.00   1.00  
Q2 [7.1, 13.4) 335 (8.2) 1.18 (1.00, 1.39) 0.044 1.14 (0.96, 1.34) 0.126 1.15 (0.97, 1.36) 0.110 1.13 (0.95, 1.34) 0.161
Q3 [13.4, 25.4) 338 (8.3) 1.19 (1.01, 1.40) 0.038 1.14 (0.97, 1.34) 0.125 1.16 (0.98, 1.37) 0.084 1.14 (0.96, 1.35) 0.124
Q4 (≥ 25.4) 357 (8.8) 1.27 (1.08, 1.49) 0.004 1.21 (1.03, 1.42) 0.024 1.22 (1.03, 1.43) 0.021 1.23 (1.04, 1.45) 0.013
P for trend 0.007a   0.034   0.150   0.128   0.122
Log-Lp(a)   1.25 (1.09, 1.43) 0.001 1.20 (1.05, 1.37) 0.009 1.21 (1.05, 1.39) 0.007 1.23 (1.07, 1.41) 0.004
  1. Abbreviations: Lp(a) Lipoprotein(a), Log log-transformed, OR Odds ratio, 95% CI 95% confidence interval
  2. Model 1: adjusted for sex, age, and ethnicity; Model 2: adjusted for CHA2DS2-VASc score; Model 3: adjusted for ethnicity, CHA2DS2-VASc score, anticoagulants, lipid-lowering medications, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1, apolipoprotein B, and red-cell distribution width
  3. aMantel-Haenszel χ2 test